SCHEMBL2252104

SCHEMBL2252104

COn1c(=O)c(-c2c(Cl)cccc2Cl)cc2c(N)nc(-c3cccc(NS(C)(=O)=O)c3)nc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 4/20 0.43
▸ HSP90AB1 P08238 4/20 0.43
▸ CYP1A2 P05177 6/20 0.40
▸ CYP3A4 P08684 6/20 0.40
▸ CYP2C19 P33261 4/20 0.40
▸ CYP2D6 P10635 3/20 0.40
▸ CLK4 Q9HAZ1 3/20 0.40
▸ TSHR P16473 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ BRD4 O60885 3/20 0.40
▸ USP2 O75604 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2250539 0.92 HAVCR2 (0.41) HSP90AA1HSP90AB1CLK4ACVR1MET
SCHEMBL15772414 0.88 HAVCR2 (0.44) HSP90AA1HSP90AB1ACVR1METABL1
SCHEMBL2245930 0.86 RIPK2 (0.41) ACVR1EGFRSRCPIK3CA
SCHEMBL2359361 0.84 NR1H2 (0.37) ACVR1ABL1EGFRSRC
SCHEMBL2246715 0.83 FGFR1 (0.39) PIK3CDABL1EGFRSRCPIK3CA
SCHEMBL2244321 0.83 DGAT1 (0.37) KDM4EHPGDBRD4ABL1EGFR
SCHEMBL2245947 0.82 BRD4 (0.42) BRD4ACVR1EGFRSRCPIK3CA
SCHEMBL2251464 0.81 PIK3CA (0.41) FYNEGFRSRCPIK3CA
SCHEMBL2249833 0.81 SRC (0.40) CYP1A2MEN1KMT2AHPGDABL1
SCHEMBL2245977 0.80 LMNA (0.42) TSHRKDM4EMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140163222-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US claimed
US-20140163006-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US claimed
US-20140163004-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US claimed
US-20140163223-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US claimed
US-20140163003-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US claimed
US-20140163005-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US claimed
US-8518958-B2 Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors FORMA THERAPEUTICS, INC. (US) 2013-08-27 — — US claimed
US-20110201594-A1 PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS Valo Health, LLC 2011-08-18 — — US claimed
EP-2084159-A1 PYRIDO Ý2, 3-D¨PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS GPC Biotech Inc. (US) 2009-08-05 — — EP claimed
WO-2008047307-A1 PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS GPC BIOTECH INC. (US) 2008-04-24 — — WO claimed
US-20140163007-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US disclosed
US-20140163005-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US disclosed
US-20140163003-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US disclosed
US-20140163223-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US disclosed
US-20140163222-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US disclosed
US-20140163004-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US disclosed
US-8518958-B2 Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors FORMA THERAPEUTICS, INC. (US) 2013-08-27 — — US disclosed
US-20110201594-A1 PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS Valo Health, LLC 2011-08-18 — — US disclosed
EP-2084159-A1 PYRIDO Ý2, 3-D¨PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS GPC Biotech Inc. (US) 2009-08-05 — — EP disclosed
WO-2008047307-A1 PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS GPC BIOTECH INC. (US) 2008-04-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163006-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 HSP90AA1 3764/4885HSP90AB1 3429/4885CYP1A2 2625/4885
US-20140163003-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 HSP90AA1 3764/4885HSP90AB1 3429/4885CYP1A2 2625/4885
US-20140163007-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 HSP90AA1 3764/4885HSP90AB1 3429/4885CYP1A2 2625/4885
US-20140163005-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 HSP90AA1 3764/4885HSP90AB1 3429/4885CYP1A2 2625/4885
US-20140163222-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 HSP90AA1 3764/4885HSP90AB1 3429/4885CYP1A2 2625/4885
US-20140163004-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 HSP90AA1 3764/4885HSP90AB1 3429/4885CYP1A2 2625/4885
US-20140163223-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 HSP90AA1 3764/4885HSP90AB1 3429/4885CYP1A2 2625/4885
US-20110201594-A1 PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS DCK, PDXK, TK1 HSP90AA1 3782/4885HSP90AB1 3415/4885CYP1A2 2593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback